Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status:
Completed
Trial end date:
2016-01-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, parallel-group study to confirm the
efficacy and safety of Dupilumab monotherapy in adults with moderate-to-severe atopic
dermatitis (AD).